Survival Outcome and EMT Suppression Mediated by a Lectin Domain Interaction of Endo180 and CD147.
Epithelial cell-cell contacts maintain normal glandular tissue homeostasis, and their breakage can trigger epithelial-to-mesenchymal transition (EMT), a fundamental step in the development of metastatic cancer. Despite the ability of C-type lectin domains (CTLD) to modulate cell-cell adhesion, it is not known if they modulate epithelial adhesion in EMT and tumor progression. Here, the multi-CTLD mannose receptor, Endo180 (MRC2/uPARAP), was shown using the Kaplan-Meier analysis to be predictive of survival outcome in men with early prostate cancer. A proteomic screen of novel interaction partners with the fourth CTLD (CTLD4) in Endo180 revealed that its complex with CD147 is indispensable for the stability of three-dimensional acini formed by nontransformed prostate epithelial cells (PEC). Mechanistic study using knockdown of Endo180 or CD147, and treatment with an Endo180 mAb targeting CTLD4 (clone 39.10), or a dominant-negative GST-CTLD4 chimeric protein, induced scattering of PECs associated with internalization of Endo180 into endosomes, loss of E-cadherin (CDH1/ECAD), and unzipping of cell-cell junctions. These findings are the first to demonstrate that a CTLD acts as a suppressor and regulatory switch for EMT; thus, positing that stabilization of Endo180-CD147 complex is a viable therapeutic strategy to improve rates of prostate cancer survival.


CONCLUSIONS
This study identifies the interaction between CTLD4 in Endo180 and CD147 as an EMT suppressor and indicates that stabilization of this molecular complex improves prostate cancer survival rates.
Department of Surgery and Cancer, Imperial College London, London, United Kingdom. Departamento de Genética, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Mercedes
M
Rodriguez-Teja
Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Julian H
JH
Gronau
Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Ai
A
Minamidate
Northern Institute for Cancer Research, Newcastle University Medical School, Newcastle upon Tyne, United Kingdom.
Steven
S
Darby
Northern Institute for Cancer Research, Newcastle University Medical School, Newcastle upon Tyne, United Kingdom.
Luke
L
Gaughan
Northern Institute for Cancer Research, Newcastle University Medical School, Newcastle upon Tyne, United Kingdom.
Craig
C
Robson
Department of Medicine, Imperial College London, London, United Kingdom.
Francesco
F
Mauri
Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Jonathan
J
Waxman
Department of Surgery and Cancer, Imperial College London, London, United Kingdom. School of Biological, Biomedical and Environmental Sciences, University of Hull, Hull, United Kingdom. j.sturge@hull.ac.uk.
Justin
J
Sturge
D051926:Basigin / Q000378:metabolism*; D045744:Cell Line, Tumor; D058750:Epithelial-Mesenchymal Transition; D006801:Humans; D008297:Male; D037241:Mannose-Binding Lectins / Q000737:chemistry* / Q000378:metabolism*; D008562:Membrane Glycoproteins / Q000737:chemistry* / Q000378:metabolism*; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000378:metabolism / Q000473:pathology*; D040901:Proteomics; D011956:Receptors, Cell Surface / Q000737:chemistry* / Q000378:metabolism*; D016019:Survival Analysis
C497886:BSG protein, human; C404106:MRC2 protein, human; D037241:Mannose-Binding Lectins; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; D051926:Basigin